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Summary
QUESTIONS: Published studies lack clear indicators of
risk and predictors of transition from Raynaud’s phenome-
non (Rp) to connective tissue diseases (CTDs). Therefore,
we aimed to study the outcomes, rates and predictors of
transition to CTDs in patients with Rp.
METHODS: A sensitive search was developed in Medline
and Embase. Observational studies reporting incidence
and risk factors of transition from Rp to a CTD were
analysed by two independent reviewers. The main out-
come was the rate of transition to a CTD; the secondary
outcome was the evaluation of predictors.
RESULTS: Of 856 articles captured, 7 selected studies
met the inclusion criteria. A total of 4051 patients with pri-
mary Rp (pRp) and 1220 transitions to overt CTDs were
recorded. The mean incidence rate of transition from pRp
to a CTD was 2.65/100 person-years (standard error [SE]
1.2, 95% confidence interval [CI] 0.44–5.73). A total of 657
patients with suspected secondary Rp (ssRp) had anti-
nuclear antibodies (ANAs) and/or capillary abnormalities;
188 transitions to CTDs were recorded, the mean inci-
dence rate of transition from ssRp to CTD was 11.01/100
person-years (SE 4.0, 95% CI 0.11–22.12), and 135 tran-
sitions to systemic sclerosis (SSc), giving a mean inci-
dence rate of transition from ssRp to SSc of 5.7/100 per-
son-years (SE 2.19, 95% CI 1.02–13.19). With respect
to patients with pRp, having ANAs without capillary ab-
normalities was associated with a risk for developing a
CTD (pooled relative risks [RR] 7.63, 95% CI 2.87–20.29),
whereas capillary abnormalities without ANAs resulted in
a weaker risk of CTD transition (RR 5.53, 95% CI
1.45–21.06). The coexistence of ANAs and abnormal cap-
illaroscopy significantly increased the risk of transition to
CTD (RR 16.96, 95% CI 6.61–43.55).
CONCLUSIONS: A low incidence rate of transition from
pRp to overt CTD was found. In spite of a possible study
selection bias, ssRp appears to have a strong risk of tran-
sition to a CTD when there is concomitant presence of
ANAs and abnormal capillaroscopy.
Key words: Raynaud’s phenomenon, ANA, connective
tissue diseases, systemic sclerosis, outcome
Introduction
Raynaud’s phenomenon (Rp) is a common condition char-
acterised by episodic reversible vasospasm of the extremi-
ties on exposure to cold or emotional stress [1]. It is closely
related to climatic conditions [2], and its prevalence varies
between studies [3, 4]; for example, in the North Ameri-
ca, the prevalence is 4 to 9% among women and 3 to 6%
among men, whereas in Europe it is 2 to 21% [5–7].
Primary Rp (pRp) is generally a benign condition charac-
terised by functional changes in blood vessels and/or their
innervation in patients without autoantibodies and normal
nail-fold capillaries. Although by definition pRp should
not progress to an overt connective tissue disease (CTD),
some population-based studies suggest that secondary Rp
(sRp) develops in 12 to 20% of subjects first diagnosed
with pRp [1, 8, 9].
Secondary Rp develops in the context of an associated dis-
order or condition, including many nonrheumatic condi-
tions (e.g., the use of vibratory tools, some compounds,
neoplasms), and rheumatic diseases (e.g., CTDs) [10]. In
relation to CTDs, Rp may be either a concomitant symp-
tom that accompanies other more specific clinical manifes-
tations or an early symptom of a developing CTD [1].
Many studies have investigated the risk of transition from
pRp to sRp and the role of different factors used during the
Rp screening phase (history, examination, investigations)
in predicting evolution toward CTDs among various popu-
lations [5, 9, 11–16].
In 1998, Spencer-Green [9] published a meta-analysis of
10 studies (639 pRp patients) that evaluated transition rates
and predictors of transition to CTD. The transition rate
found (3.2 transitions per 100 patient-years of follow-up)
was low, especially in consideration of the time from Rp
onset (1.4 per 100 patient-years). Abnormal nail-fold cap-
illaries at study entry, even when associated with positive
antinuclear antibody (ANA) tests, was the chief predictor
of evolution to CTDs [9].
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In recent years, significant efforts have been made to
achieve an early diagnosis of CTDs and new classification
criteria have been released [17, 18].
The present systematic review and meta-analysis aimed to
add new evidence to the previous work by Spencer-Green
[9], supposing that the most recent literature could provide
a more accurate estimation of clinical outcomes and risk
factors for transitions to sRp.
Methods
Literature search
The reporting of the study was guided by the MOOSE
Statement [19]. A comprehensive systematic literature
search was undertaken, which included studies published
between July 1996 and August 2014, and an updated
search was carried out in May 2016 to capture newly pub-
lished studies. The databases used were Medline (via
PubMed) and Embase. The search strategy was intended
to uncover all relevant papers reporting on an adult pop-
ulation with Rp and dealing with any aspect of transition
to overt CTDs, such as incidence and risk factors. The full
search strategy is provided in supplementary table S1 (ap-
pendix 1). During the first analysis, two reviewers (F.I.,
C.T.) independently screened titles/abstracts and the full
papers were sought if relevant. Any duplicate articles were
excluded. Reference lists of review articles were also ex-
amined for relevant studies. In cases of disagreement, a de-
cision was reached by consensus or, if necessary, a third re-
viewer (N.U.) was consulted.
Study selection
Study selection was by N.U. and C.C. To be eligible, stud-
ies needed to meet the following criteria: adult participants
(>16 years old) with Rp classified as primary or secondary;
longitudinal observational studies (prospective or retro-
spective) and case-control studies were considered suitable
in scope of review; studies reporting the incidence of tran-
sition of Rp to CTDs and/or potential risk factors; studies
with a detailed description of parameters used to define
and classify Rp; studies with at least the abstract in Eng-
lish.
Exclusion criteria were: studies assessing treatment of Rp;
studies involving patients with a clear definition of sec-
ondary Rp; studies not reporting the criteria for diagnosing
a CTD; studies assessing occupational Rp; unpublished
material, case reports, editorials, letters or reviews. Where
different articles of the same author appeared to describe
same patients more than once, only the article providing
the most detailed information on the patients was included.
Data extraction and synthesis
Data extraction from each article was by N.U. and C.C. An
independent reviewer (F.I.) ensured the quality of data ex-
traction. Data concerning study design, country, age range,
gender ratio and total number of participants, exposure to
ANAs, capillaroscopy, and development of a CTD were
collected in ad hoc forms. If the same study population was
reported in more than one article, we used the article with
data most clearly presented. Where possible, the raw out-
comes were extracted (primary outcome: number of per-
sons developing an overt CTD) for each group (exposed to
ANAs and/or abnormal capillaroscopy vs not exposed) and
the effect estimates were calculated. Where data retrieval
from the articles was difficult, the authors were contacted
by email.
To assess the methodological quality of nonrandomised
observational studies, we used the Newcastle-Ottawa scale
(NOS) recommended by the Cochrane Collaboration. Ac-
cording to the NOS [20, 21], a study can be awarded a
maximum of one point for each numbered item within
the “selection” and “outcome” categories (four and three
items, respectively); a maximum of two points can be giv-
en for comparability (one item). The quality of the includ-
ed studies was independently evaluated by N.U. and C.C.
and rated by consensus. Studies were considered of good
quality if the total score was ≥5. No studies were excluded
from data analysis on the basis of the quality score grading.
Case definitions
Patients with Rp were categorised into two distinct clinical
entities: (1) patients with pRp defined according to the
Leroy and Medsger criteria (i.e., no history or physical
findings suggestive of a secondary cause, normal capil-
laroscopy, negative serological findings) [22]; (2) patients
with Rp associated with ANAs and/or abnormal capil-
laroscopy, even if associated with symptoms or physical
findings suggestive of a secondary cause, but without ful-
filling criteria for a definite CTD.
Up to now, the latter condition has been variously defined
and there is no consensus among experts. In our analysis,
we refer to it as “suspected secondary Rp” (ssRp). Patients
fulfilling the definition of pRp and ssRp were analysed
separately for transition rates.
We were aware that the ssRp group could be heterogeneous
in terms of prognosis, so we decided to split the analysis
on risk of transition according to the following three sub-
groups: (1) patients with ANAs positive without capil-
laroscopy abnormalities (Rp with immune signature); (2)
patients with ANAs negative with capillaroscopy abnor-
malities (Rp with vascular signature); (3) patients with
ANAs positive and abnormalities on capillaroscopy (Rp
with immune and vascular signatures).
As capillaroscopy abnormalities, we considered findings
such as giant capillaries, decrease in the capillary number,
capillary derangement and microhaemorrhages, which are
required for the definition of “scleroderma pattern” in ac-
cordance with the description reported either by Maricq
[23] or by Cutolo [24].
Statistical analysis
Individual data to calculate the incidence of transition were
derived from the original reports from the information pro-
vided in each study. Cumulative incidences and 95% confi-
dence intervals (CIs) were transformed into incidence rate
data (incidence per 100 person-years). Relative risks (RR)
and 95% CIs were calculated to present the association be-
tween risk factors (ANA positivity and capillaroscopy ab-
normalities) and transition to CTD. The presence of statis-
tical heterogeneity was evaluated with the chi-squared test
and a p-value <0.1 was considered significant; inconsisten-
cy across studies was quantified as the I2 statistic, where a
value >50% was considered to indicate substantial hetero-
geneity. A Mantel-Haenszel random-effects model for di-
chotomous variables was used to pool the data into a meta-
analysis.
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All statistical analyses were carried out using Stata V.13.0;
RevMan and Comprehensive meta-analysis software were
used to pool data on RR and incidence rates, respectively.
Results
In total, 856 references were retrieved in the initial search
strategy in PubMed and Embase. Of these, 826 were ex-
cluded as duplicates or after title/abstract screening. Thirty
articles were retrieved for full paper review, of which sev-
en fulfilled the inclusion criteria [5, 11–16]. The review
flow process is outlined in fig. 1.
The included studies are listed in table 1, with a description
of the study design, population, setting and diagnosis at
baseline [5, 11–16], as well as NOS quality ratings.
Among the seven studies included, two analysed cohorts
of patients with pRp, one included only patients with ssRp,
and four reported data about both groups of patients. No
case-control studies satisfied the inclusion criteria for this
meta-analysis.
As shown in table 2A, a total of 4051 unique patients with
pRp were included in six studies. Three articles [5, 12, 15]
reported information about gender (3394 patients, 88.1%
were women); five studies [5, 11, 12, 15, 16] provided
data about the age at baseline (mean 43.1 years, range
39.8–47.0 years); four articles [5, 11, 15, 16] reported the
average age at onset of Rp (3712 patients, mean 34.1 years,
range 28.5–38.1 years) and the average of pRp duration
(3712 patients, mean 8.0 years, range 5.3–11.6 years).
As shown in table 2B, among five studies [5, 11–14] with
657 ssRp patients, four [5, 11–13] provided information
about gender (281 patients, 89.0% were women) and age
at the time of study entry (281 patients, median 44.1 years,
range 37.5–48.3 years); three articles [5, 11, 13] reported
the average age at onset of Rp (122 patients, mean 37.0
years, range 34.5–39.0 years) and in these patients Rp had
been present for a mean of 5.7 years (range, 3.0–8.2 years)
before study entry. The effects of age and sex on transition
to a CTD were not analysed owing to the lack of data.
Table 1: Characteristics of the seven studies included and the quality of evidence assessment.
Characteristics Quality of evidence assessment with NOSSource
Study design Total no. of partici-
pants and diagnosis
Male/
female
Setting, country Selection Comparability Outcome Overall
De Angelis 2003
[11]
Cohort, prospec-
tive
20
pRp and ssRp
6/14 Hospital, Italy 4 0 1 5
Hirschl 2006 [5] Cohort, prospec-
tive
282
pRp and ssRp
61/221 Hospital, Austria 4 2 3 9
Koenig 2008 [14] Cohort, prospec-
tive
586
pRp and ssRp
---* Hospital, Canada 4 2 2 8
Ingegnoli 2010
[12]
Cohort, retrospec-
tive
288
pRp and ssRp
33/255 Hospital, Italy 4 0 1 5
Pavlov- Doli-
janovic 2012 [15]
Cohort, retrospec-
tive
3029 pRp 333/2696 Hospital, Serbia 2 0 2 4
Bernero 2013
[16]
Cohort, prospec-
tive
412 pRp -- Hospital, Italy 4 0 2 6
Valentini 2014
[13]
Cohort, prospec-
tive
60 ssRp 4/56 Hospital, Italy 3 2 2 7
*referred to the overall population pRp: primary Raynaud’s phenomenon; ssRp: suspected secondary Raynaud’s phenomenon; NOS: Newcastle-Ottawa scale. A study can be
awarded a maximum of one point for each numbered item within the Selection and Outcome categories (maximum four and three points, respectively). A maximum of two points
can be given for Comparability. The overall score ranges from 0 to 9. Quality scale does not imply that items are of equal relevant importance.
Table 2: Summary of findings on primary Raynaud’s phenomenon (A) and on suspected secondary Raynaud’s phenomenon (B).
(A) Primary Ray-
naud’s phenome-
non (I2 99.5%, tau2
9.828)
Source No. pa-
tients
Average fol-
low-up
(person years)
Average age at
onset of Rp
(years)
Average age at
baseline
(years)
No. of
transitions to
overt CTD
No. of transi-
tion to overt
SSc
Incidence
rate to overt CTD
(per 100 person-years)
Incidence rate to
overt SSc
(per 100 person-
years)
Pavlov-Dolijanovic
2012 [15]
3029 14 539 38.1 43.4 1123 263 7.72 1.809
Ingegnoli 2010 [12] 129 302 -- 47.0 10 1 3.31 0.331
Koenig 2008 [14] 210 840 -- --- 0 0 0.06 0.056
De Angelis
2003 [11]
35 105 33.9 39.8 0 0 0.32 0.323
Hircshl 2006 [5] 236 2643 28.5 40.2 19 5 0.72 0.189
Bernero 2013 [16] 412 1813 36 45 68 52 3.75 2.870
Total/mean 4051 20 242 34.1 43.1 1220 321 6.02 1.58
(B) Suspected secondary Raynaud’s phenomenon (I2 92%, tau2 40.096)
Valentini 2014 [13] 60 180 34.5 37.5 21 21 11.667 11.667
Ingegnoli 2010 [12] 159 253 -- 48.3 66 33 26.087 13.043
Koenig 2008 [14] 376 1654 -- -- 80 74 4.837 4.474
De Angelis 2003 [11] 16 48 37.6 43.4 2 2 4.167 4.167
Hirschl 2006 [5] 46 230 39.0 47.2 19 5 8.261 2.174
Total/mean 657 2365 37 44.1 188 135 7.94 5.70
CTD = connective tissue disease
Systematic review Swiss Med Wkly. 2017;147:w14506
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 11
Clinical and laboratory variables were remarkably hetero-
geneous, including at the baseline evaluation, and the iden-
tification of precise clinical predictors of transition was
limited. However, in all the seven studies (4708 unique
participants), ANAs were measured and nail-fold capil-
laroscopy was performed. Five studies provided informa-
tion about ANA assessment by use of either an indirect im-
munofluorescence (IFI) test on Hep-2 cells [5, 12, 14, 15]
or by both IFI and the enzyme-linked immunosorbent as-
say [11]; in six studies [5, 11–14, 16], nail-fold capillary
abnormalities were defined as proposed in the definitions
of scleroderma patterns in accordance with Maricq [23] or
Cutolo [24].
Rate of transition from pRP to a CTD
A total 4051 pRp patients with a cumulative mean follow-
up of 20 242 person-years (mean follow-up 5.0, range
2.3–11.2 years) were included; 1220 (30.1%) transitions
to an overt CTD were recorded, giving a cumulative in-
cidence rate of 6.02 per 100 person-years (table 2A). The
mean incidence rate of transition from pRp to a CTD was
2.65 per 100 person-years (standard error [SE] 1.2, 95% CI
0.44–5.73). The higher transition rate was reported in 2012
by Pavlov-Dolijanovic [15] (7.7 per 100 person-years), and
the lowest (no transitions) by De Angelis [11] and Koenig
[14].
Among pRp patients, 321 (73.7%) developed systemic
sclerosis (SSc), a cumulative incidence rate of 1.58 per 100
person-years, ranging from 2.87 [16] to 0.06 [14] per100
person years (supplementary fig. S1 and table S2 in ap-
pendix 1). The mean incidence rate of transition from pRP
to SSc was 0.93 per 100 person-years (SE 0.47, 95% CI:
0.27–2.13).
A total of 383 (31.4%) patients developed undifferentiated
connective tissue disease, 145 (11.9%) systemic lupus ery-
thematosus (SLE), 104 (8.5%) Sjögren's syndrome, 115
(9.4%) rheumatoid arthritis, 61 (5%) overlap syndromes,
30 (2.5%) mixed connective tissue disease, 30 (2.5%) sys-
Figure 1: Flow diagram of the systematic review process.
temic vasculitis, 26 (2.1%) poly/dermatomyositis, 5
(0.4%) antiphospholipid syndrome (fig. S2).
Because of the great heterogeneity among studies regard-
ing sample size, follow-up duration and outcomes, data on
transition rates were not meta-analysed.
Rate of transition from ssRp to a CTD
Five studies included 657 ssRp patients with a cumulative
mean follow-up of 2365 person-years (mean follow-up 3.6,
range 1.6–5.0 years); 188 (28.6%) transitions to a CTD
were recorded, giving a cumulative incidence rate of 7.94
per 100 person-years (table 2B). The mean incidence rate
of transition from ssRp to a CTD was 11.01 per 100 per-
son-years (SE 4.0, 95% CI 0.11–22.12). Ingegnoli [12]
recorded the highest transition rate to CTDs (26.09 per 100
person-years), and De Angelis [11] the lowest (4.17 per
100 person-years).
Among these transitions, 135 (71.8%) were to SSc, a cu-
mulative incidence rate of 5.70 per 100 person-years
(range 2.17–13.04) (supplementary fig. S1 in appendix
1 and table 2B). The mean incidence rate from ssRP to
SSc was 7.10 per 100 person-years (SE 2.19, 95% CI
1.02–13.19).
Six (3.2%) patients developed mixed connective tissue dis-
ease, 7 (3.7%) SLE, 2 (1.1%) Sjögren's syndrome, 13
(6.9%) rheumatoid arthritis, 22 (11.7%) undifferentiated
connective tissue disease, 3 (1.6%) poly/dermatomyositis;
none developed overlap syndromes, antiphospholipid syn-
drome or systemic vasculitis (fig. S2).
Because of the great heterogeneity among studies regard-
ing sample size, follow-up duration and outcomes, data on
transition rates were not meta-analysed.
Predictors of transition
All the studies identified ANAs and nail-fold capillary ab-
normalities as predictors of transition to a CTD. In particu-
lar (fig. 2A), compared with the patients with pRp (ANAs
negative and normal capillaries), having either positive
ANAs without capillary abnormalities (immune signature)
or capillary abnormalities with negative ANAs (vascular
signature) indicated a great risk of developing a CTD:
pooled RR 7.63, 95% CI 2.87–20.29, and pooled RR 5.53,
95% CI 1.45–21.06, respectively. The coexistence of
ANAs and abnormal capillaries (immune and vascular sig-
nature) significantly increased the risk of transition to a
CTD (RR 16.96, 95% CI 6.61–43.55). However, there was
substantial heterogeneity among studies for this outcome.
Having ANAs positive without capillary abnormalities
(immune signature) indicated a substantial risk of devel-
oping SSc (pooled RR 13.23, 95% CI 4.72–37.06), as did
the presence of capillary abnormalities without ANAs (RR
11.81, 95% CI 4.07–34.25) (vascular signature). The co-
existence of ANAs and abnormal nail-fold capillaries (im-
mune and vascular signature) significantly increased the
risk of transition to SSc (RR 40.45, 95% CI 14.02–116.77).
For this outcome, the included studies showed no signifi-
cant heterogeneity (figs 2B and 2C).
ANA positivity without capillary abnormalities (immune
signature) was associated with a risk of developing CTDs
other than SSc (pooled RR 4.18, 95% CI 1.93–9.06), as did
the presence of capillary abnormalities without ANAs (RR
3.42, 95% CI 1.50–7.81) (vascular signature); coexistence
of ANAs and capillary abnormalities (immune and vascu-
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lar signature) significantly increased the risk of transition
to a non-SSc CTD (RR 4.60, 95% CI 1.37–15.44).
Discussion
Statement of principal findings
The present systematic review and meta-analysis was
planned to add new evidence to the previous work by
Spencer-Green published in 1998 [9]. According to
Spencer-Green, a patient presenting only with Rp, without
signs suggestive for a CTD, could be reassured: this con-
dition is likely to have a benign course. Overall, 4708 Rp
patients were included in the present analysis; according to
our case definitions, 4051 had pRp and 657 had ssRp. A to-
tal of 1408 transitions to CTDs were recorded (30.1% from
pRp, 28.6% from ssRp) during the follow-up.
The presence of autoantibodies (even without any speci-
ficity) should be carefully considered when assessing pos-
sible evolution to a secondary form. The coexistence of
abnormalities of capillaries should raise suspicion for pos-
sible evolution to SSc and requires watchful monitoring
and early intervention strategies.
Our data showed that ANA positivity is an important pre-
dictive factor for the evolution to CTDs other than SSc.
In particular, most of the transitions to CTDs were toward
undifferentiated connective tissue disease and SLE; this is
not surprising as Rp is one of the most frequently report-
ed symptoms in patients with these diseases [25], although
Rp is not mentioned in proposed undifferentiated connec-
tive tissue disease classification criteria, nor in the newest
classification criteria for SLE [26]. Therefore, these data
highlight the importance of appropriate monitoring strate-
gies for patients with Rp and ANAs.
Strengths and weakness of the study
The use of two databases might be considered a limitation.
A source of uncertainty is the great heterogeneity among
studies, especially for transition rate outcome, which was
probably due to great variability in clinical assessment; this
could misrepresent the average rate. Our systematic liter-
ature review highlighted the variety of nomenclature for
patients with Rp, positive ANAs, and/or nail-fold capil-
lary abnormalities, even in association with symptoms or
physical findings suggestive of a secondary cause but with-
out fulfilling the diagnostic criteria for a definite CTD.
This is still a matter of debate: to overcome this problem
we called these patients “suspected secondary Rp” with an
“immune” or a “vascular” signature.
In order to increase consistency and accuracy, we decided
to consider data for pRp and ssRp separately. We are aware
Figure 2A: Predictors of transition to connective tissue diseases in patients with Raynaud’s phenomenon with immune signature.
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that this choice reduced the comparability of our results
with Spencer-Green analysis [9]. However, we think this
approach guarantees more clinically meaningful results; as
confirmation, different outcomes were reported in the two
conditions.
Higher transition rates were reported by two retrospective
studies [12, 27], thus we could hypothesise that there was
an assessment bias in the baseline evaluation, which artifi-
cially increased the evolution rate.
In the analysis of ssRp transition to SSc, very low hetero-
geneity among studies was found. This is in line with an
increased awareness of SSc-specific prognostic factors for
early diagnosis of the disease.
All studies included in this meta-analysis derived from ter-
tiary referral centres for CTDs; this could represent a re-
ferral bias, increasing transition rates to CTD because the
most severe cases are generally addressed to tertiary hospi-
tals.
Finally, data on evolution to non-SSc CTDs were available
in only two studies [5, 12]; the focus on SSc could have
caused underestimation of transition to CTDs other than
SSc.
Comparison with other studies
These results are in line with Spencer-Green’s [9] previous
observation: a transition rate to CTDs of 3.2 ± 2.0 per 100
person-years (range 0.8–7.0).
We decided to analyse separately patients with Rp and
ANA positivity and/or capillary abnormalities (immune
and/or vascular signature Rp) because of the growing ev-
idence of the role of these variables on disease outcomes
[1, 10]. As expected, the transition rate was significantly
greater in the ssRp group (10.61 and 6.57 per 100 person-
years for transition to any CTD and to SSc, respectively).
Indeed, our analysis confirms that the two conditions (pRp
and ssRp) have different prognoses and should be consid-
ered separately; besides, the presence of ANAs and cap-
illaroscopy abnormalities (especially coexistence of both
conditions) are associated with significant risk of transition
to a definite CTD and, in particular, SSc.
These data confirmed that patients with Rp and SSc-mark-
er autoantibodies and/or typical nail-fold capillaroscopic
ﬁndings, but no other organ manifestations (thus not ful-
filling classification criteria for SSc), may be identified
as “early SSc” and often present preclinical organ dys-
function [28, 29]. Our data are also in line with the Very
Early Diagnosis of Systemic Sclerosis (VEDOSS) project
in which the presence of specific findings (including Rp,
puffy fingers and ANA positivity), defined as “red flags”,
is recommended to raise a strong suspicion of a diagnosis
of very early SSc and requires further assessments [17].
The utility of nail-fold capillaroscopy as a tool to confirm
the suspicion is also well established [30, 31].
Figure 2B: Predictors of transition to connective tissue diseases in patients with Raynaud’s phenomenon with vascular signature.
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Implications
Rp is a common condition in the general population and
the identification of patients with Rp who are at higher risk
of developing a secondary form is still a challenge. This
represents an early opportunity to identify patients likely
to develop a CTD, with important consequences for man-
agement and monitoring strategies. This review adds fur-
ther data to the existing literature; the work-up provided
more comprehensive data than those reported in previous
meta-analysis [9], thus we can hypothesize our estimations
are more accurate. In conclusion, in consideration of the
significant prognostic difference between what we consid-
ered pRp versus ssRp, these data relaunch the great debate
about the classification of patients with Rp and only ANA
positivity (immune signature) or only capillary abnormali-
ties (vascular signature). Further prospective studies and a
broader consensus appear essential.
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Appendix 1 Supplementary tables and figures
Table S1: Search Strategy. Results were filtered for “humans”, “adults”, “English” and search was ranged between 1st July 1996 and 31st May 2016.
EMBASE 'raynaud phenomenon'/exp OR 'raynaud disease' OR 'raynaud phenomenon' OR 'raynaud syndrome' OR 'raynaud`s disease' OR 'disease, raynaud' OR
'syndrome, raynaud' AND ('prognosis'/exp OR 'prognosis' OR 'disease course'/exp OR 'clinical course' OR 'disease course' OR 'disease development'
OR 'disease evolution' OR 'disease progression') AND ('systemic sclerosis'/exp OR 'generalised scleroderma' OR 'generalized scleroderma' OR 'pro-
gressive scleroderma' OR 'progressive sclerodermia' OR 'progressive sclerosis, systemic' OR 'progressive systemic sclerosis' OR 'scleroderma, gener-
alised' OR 'scleroderma, generalized' OR 'scleroderma, progressive' OR 'scleroderma, systemic' OR 'sclerosis, progressive systemic' OR 'sclerosis, sys-
temic' OR 'sclerosis, systemic progressive' OR 'systemic progressive sclerosis' OR 'systemic scleroderma' OR 'systemic sclerosis' OR 'systemic
sclerosis, progressive' OR 'polymyositis'/exp OR 'polymyositis' OR 'mixed connective tissue disease'/exp OR 'connective tissue disease, mixed' OR
'mctd' OR 'mixed collagen disease' OR 'mixed connective tissue disease' OR 'mixed connective tissue disorder' OR 'dermatomyositis'/exp OR 'dermato-
myositides' OR 'dermatomyositis' OR 'systemic lupus erythematosus'/exp OR 'lupus erythematosus, systemic' OR 'systemic lupus erythematosus' OR
'connective tissue disease'/exp OR 'connective tissue disease' OR 'connective tissue diseases' OR 'connective tissue disorder') AND ('cohort analy-
sis'/exp OR 'analysis, cohort' OR 'cohort analysis' OR 'cohort studies' OR 'cohort study' OR 'longitudinal study'/exp OR 'longitudinal evaluation' OR 'lon-
gitudinal studies' OR 'longitudinal study' OR 'follow up'/exp OR 'prospective study'/exp OR 'prospective method' OR 'prospective studies' OR 'prospec-
tive study' OR 'study, prospective' OR 'retrospective study'/exp OR 'retrospective design' OR 'retrospective studies' OR 'retrospective study' OR 'study,
retrospective')
Medline via PubMed ((((((((((((Raynaud's disease[Text Word]) OR Raynaud's disease[MeSH Terms])) OR ((Raynaud's phenomenon[Text Word]) OR Raynaud's phenome-
non[MeSH Terms])) OR ((Raynaud phenomenon[Text Word]) AND Raynaud phenomenon[MeSH Terms])) OR ((Raynaud syndrome[Text Word]) OR
Raynaud syndrome[MeSH Terms])) OR ((Syndrome, Raynaud[Text Word]) OR Syndrome, Raynaud[MeSH Terms])) OR ((Raynaud sign[Text Word]) OR
Raynaud sign[MeSH Terms])) OR ((Raynaud disease[Text Word]) OR Raynaud disease[MeSH Terms])) OR ((Disease, Raynaud[Text Word]) OR Dis-
ease, Raynaud[MeSH Terms]))) AND (((((Disease Progression[Text Word]) OR Disease Progression[MeSH Terms])) OR ((Disease transition[Text Word])
OR Disease transition[MeSH Terms])) OR (prognosis[Text Word]) OR ((disease course[Text Word]) OR disease course[MeSH Terms])) OR ((disease de-
velopment[Text Word]) OR disease development[MeSH Terms])) OR ((disease evolution[Text Word]) OR disease evolution[MeSH Terms])) OR ((clinical
course[Text Word]) OR clinical course [MeSH Terms])))) AND (((((((((((((((((((((((syndrome crest[Text Word]) OR syndrome crest[MeSH Terms])) OR
((limited scleroderma[Text Word]) OR limited scleroderma[MeSH Terms])) OR ((diffuse scleroderma[Text Word]) OR diffuse scleroderma[MeSH Terms]))
OR ((systemic sclerosis[Text Word]) OR systemic sclerosis[MeSH Terms])) OR ((systemic scleroderma[Text Word]) OR systemic scleroderma[MeSH
Terms])) OR ((systemic progressive[Text Word]) OR systemic progressive[MeSH Terms])) OR ((sclerosis[Text Word])) OR ((progressive systemic sclero-
sis[Text Word]) OR progressive systemic sclerosis[MeSH Terms])) OR ((progressive sclerodermia[Text Word]) OR progressive sclerodermia[MeSH
Terms])) OR ((progressive scleroderma[Text Word]) OR progressive scleroderma[MeSH Terms])) OR ((generalized scleroderma[Text Word]) OR gener-
alized scleroderma[MeSH Terms])) OR ((generalised scleroderma[Text Word]) OR generalised scleroderma[MeSH Terms]))) OR ((polymyositis[Text
Word]) OR polymyositis[MeSH Terms])) OR ((mixed connective tissue disease[Text Word]) OR mixed connective tissue disease[MeSH Terms])) OR
((dermatomyositis[Text Word]) OR dermatomyositis[MeSH Terms])) OR ((systemic lupus erythematosus[Text Word]) OR systemic lupus erythemato-
sus[MeSH Terms])) OR ((undifferentiated connective tissue disease[Text Word]) OR undifferentiated connective tissue disease[MeSH Terms])) OR
((connective tissue disease[Text Word]) OR connective tissue disease[MeSH Terms])) OR ((connective tissue disorder[Text Word]) OR connective tissue
disorder[MeSH Terms])))) AND ((((((((((((((((((retrospective study[Text Word]) OR retrospective study[MeSH Terms])) OR ((retrospective studies[Text
Word]) OR retrospective studies[MeSH Terms])) OR ((prospective studies[Text Word]) OR prospective studies[MeSH Terms])) OR ((prospective
study[Text Word]) OR prospective study[MeSH Terms])) OR ((longitudinal studies[Text Word]) OR longitudinal studies[MeSH Terms])) OR ((longitudinal
study[Text Word]) OR longitudinal study[MeSH Terms])) OR ((Review[Text Word])) OR ((cohort studies[Text Word]) OR cohort studies[MeSH Terms]))
OR ((cohort study[Text Word]) OR cohort study[MeSH Terms])) OR ((clinical trial[Text Word]) OR clinical trial[MeSH Terms])) OR ((clinical drug trial[Text
Word]) OR clinical drug trial[MeSH Terms])) OR ((trial clinical[Text Word]) OR trial clinical[MeSH Terms]))))
Table S2: Exclusion reasons for 23 manuscripts.
Reason of exclusion No. of studies
Studies not reporting antinuclear antibodies and nail-fold capillaroscopy assessment or not declaring the classification criteria for prima-
ry Raynaud’s phenomenon according to LeRoy and Medsger at baseline
11
Studies involving patients with a clear definition of secondary Raynaud’s phenomenon to overt connective tissue diseases at baseline 5
Studies with outcomes other than evolution to overt connective tissue diseases 4
Studies not declaring the classification criteria for diagnosing a connective tissue disease 2
Where different articles by the same author appeared to describe the same patients more than once, only the article providing the most
detailed information about the follow-up status of the patients was included
1
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Figure S1: Forest plots showing the incidence rate of transition to systemic sclerosis of primary and suspected secondary Raynaud’s phe-
nomenon as per 100 person-years.
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Figure S2: Connective tissue diseases developed in patients with primary Raynaud’s phenomenon (white column) and suspected secondary
Raynaud’s phenomenon (black column).
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